Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299793 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL9057558 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL9055032 | 0.98 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL24179519 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL27987174 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL990336 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL8059750 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL22081089 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL7352304 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL28904441 | 0.81 | HTR2A (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223751-A1 | BENZAMIDE COMPOUND AND USE THEREOF | Humanwell Healthcare (Group) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2020115190-A1 | NOVEL ANTIBACTERIAL 3\"-DERIVATIVES OF 4,6-DISUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS | AGILEBIOTICS B.V. (NL) | 2020-06-11 | — | — | WO | disclosed |
| US-9242984-B2 | Pyrazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | SLC6A2 4871/4885SLC6A4 4836/4885SLC6A3 4867/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | SLC6A2 1344/4885SLC6A4 1036/4885SLC6A3 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.